首頁 > 市場調查報告書 > 製藥

膀胱過動症治療市場規模、佔有率和成長分析（按治療方法、給藥途徑、分銷管道和地區分類）－2025-2032年產業預測

市場調查報告書

商品編碼

1865258

膀胱過動症治療市場規模、佔有率和成長分析（按治療方法、給藥途徑、分銷管道和地區分類）－2025-2032年產業預測

Overactive Bladder Treatment Market Size, Share, and Growth Analysis, By Treatment Type (Anticholinergics, Beta-3 Adrenergic Agonists), By Route of Administration (Oral, Intravesical), By Distribution Channel, By Region - Industry Forecast 2025-2032

出版日期: 2025年11月05日 | 出版商:

SkyQuest | 英文 193 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

全球膀胱過動症(OAB) 治療市場規模預計在 2023 年達到 35 億美元，從 2024 年的 36.7 億美元成長到 2032 年的 53.4 億美元，在預測期（2025-2032 年）內複合年成長率為 4.8%。

全球膀胱過動症(OAB) 治療市場正經歷強勁成長，這主要得益於老年人口的不斷成長。老年人更容易因老齡化相關變化而出現膀胱功能障礙。這種人口結構的變化與頻尿和尿急的發生率升高密切相關，從而推動了對有效治療方法的需求。同時，治療方案的持續創新正在重塑市場格局。傳統的抗膽鹼能藥物由於副作用而降低了患者的依從性，而BETA3腎上腺素受體促效劑、肉毒桿菌注射和神經調控療法等新技術則提供了更安全、耐受性更好的替代方案。這些進步不僅改善了臨床療效，也促進了患者和醫生對新療法的接受度，使得療效的提高和副作用的最小化成為OAB治療領域持續擴張的關鍵因素。

全球膀胱過動症治療市場促進因素

全球膀胱過動症治療市場的擴張受到全球人口老化加劇的顯著影響。隨著老齡化，膀胱肌肉功能和神經調節能力自然下降，導致膀胱過動症的發生率增加。老年族群中膀胱過動症盛行率的上升，使得對有效治療方案的需求日益成長。這促使人們對各種治療方法的需求增加，例如藥物治療、神經調節技術和微創手術，所有這些方法都旨在滿足老年族群的需求，從而促進整體市場成長。

阻礙因素全球膀胱過動症治療市場的因素

全球膀胱過動症治療市場面臨許多挑戰，其中最主要的原因是各種治療方法，尤其是抗膽鹼能藥物的副作用。常見的副作用包括口乾、便秘和認知障礙，這些都可能導致患者，特別是老年患者，對處方治療的依從性降低。這種不滿意往往會導致治療中斷，進而阻礙市場擴張。因此，人們越來越需要更安全的替代方案，例如BETA3促效劑和微創方法，以解決這些問題，同時改善患者在控制膀胱過動症症狀的療效和滿意度。

全球膀胱過動症治療市場趨勢

全球膀胱過動症治療市場正見證著神經調控療法，特別是脛神經刺激和薦椎神經刺激療法的顯著成長。這些微創、基於器械的治療方法因其能夠提供持續的症狀緩解且副作用少於傳統藥物療法而日益受到青睞。患者和醫療專業人員對這些療法的認知不斷提高，加上令人鼓舞的臨床結果，促使人們對這些創新治療方法的偏好顯著增強。這種轉變不僅改善了患者的生活品質，也推動了全球膀胱過動症治療市場的整體擴張。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2024 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2024 年）
主要企業簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2022-2024年營收年比比較

主要企業簡介

Astellas Pharma（Japan）
Pfizer Inc.（United States）
AbbVie Inc.（United States）
Medtronic Plc（Ireland）
Sumitomo Pharma Co., Ltd.（Japan）
Teva Pharmaceutical Industries Ltd.（Israel）
Johnson & Johnson（United States）
Hisamitsu Pharmaceutical Co., Inc.（Japan）
Endo International plc（Ireland）
Cipla Ltd.（India）
Sun Pharmaceutical Industries Ltd.（India）
Lupin Ltd.（India）
Dr. Reddy's Laboratories Ltd.（India）
Coloplast（Denmark）
Axonics, Inc.（United States）
Boston Scientific（United States）
Kyorin Pharmaceutical Co., Ltd.（Japan）
Macleods Pharmaceuticals Ltd.（India）
Organon（United States）
Viatris Inc.（United States）

結論與建議

簡介目錄

Product Code: SQMIG35D2367

Global Overactive Bladder Treatment Market size was valued at USD 3.5 billion in 2023 and is poised to grow from USD 3.67 billion in 2024 to USD 5.34 billion by 2032, growing at a CAGR of 4.8% during the forecast period (2025-2032).

The Global Overactive Bladder (OAB) Treatment Market is experiencing robust growth driven by a rising aging population, which is more susceptible to bladder dysfunction due to age-related changes. This demographic shift correlates with higher occurrences of urinary urgency and frequency, escalating the demand for effective treatment options. Alongside this, continuous innovation in therapeutic solutions is reshaping the market. Traditional anticholinergic medications have seen reduced patient compliance due to side effects, but advancements such as B3-adrenoceptor agonists, Botox injections, and neuromodulation therapies offer safer and more tolerable alternatives. These developments not only enhance clinical outcomes but also foster greater patient and physician adoption, positioning improved efficacy and minimized side effects as pivotal factors in the ongoing expansion of the OAB treatment landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Overactive Bladder Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Overactive Bladder Treatment Market Segments Analysis

Global Overactive Bladder Treatment Market is segmented by Treatment Type, Route of Administration, Distribution Channel and region. Based on Treatment Type, the market is segmented into Anticholinergics, Beta-3 Adrenergic Agonists, Neuromodulation, Botulinum Toxin Injections and Behavioral Therapies. Based on Route of Administration, the market is segmented into Oral, Intravesical, Transdermal and Injectable. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Overactive Bladder Treatment Market

The expansion of the global overactive bladder treatment market is significantly influenced by the growing aging population worldwide. As individuals age, there is a natural decline in bladder muscle functionality and neurological regulation, resulting in a higher incidence of overactive bladder. This increased prevalence among older adults leads to a greater need for effective management options. Consequently, there is a rising demand for various treatment modalities, including pharmacological therapies, neuromodulation techniques, and minimally invasive surgical procedures, which collectively contribute to the overall growth of the market by addressing the needs of this demographic.

Restraints in the Global Overactive Bladder Treatment Market

The Global Overactive Bladder Treatment market faces significant challenges due to the adverse effects associated with various treatment options, especially anticholinergics. Common side effects, including dry mouth, constipation, and cognitive impairment, particularly among elderly patients, can lead to decreased patient adherence to prescribed therapies. This dissatisfaction often results in patients discontinuing their treatment, thereby hindering market expansion. Consequently, there is a growing demand for safer alternatives, such as B3-adrenergic agonists or minimally invasive approaches, to address these issues while improving patient outcomes and satisfaction in managing overactive bladder symptoms.

Market Trends of the Global Overactive Bladder Treatment Market

The global overactive bladder treatment market is witnessing a significant trend towards the rising adoption of neuromodulation therapies, notably tibial and sacral nerve stimulation. These minimally invasive, device-based interventions are favored for their capacity to deliver lasting symptom relief while presenting fewer adverse effects compared to traditional pharmacological options. As awareness among patients and healthcare providers continues to grow, alongside promising clinical outcomes, there is a marked increase in the preference for these innovative treatments. This shift not only enhances patient quality of life but also propels the overall expansion of the overactive bladder treatment market on a global scale.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Overactive Bladder Treatment Market Size by Treatment Type & CAGR (2025-2032)

Market Overview
Anticholinergics
Beta-3 Adrenergic Agonists
Neuromodulation
Botulinum Toxin Injections
Behavioral Therapies

Global Overactive Bladder Treatment Market Size by Route of Administration & CAGR (2025-2032)

Market Overview
Oral
Intravesical
Transdermal
Injectable

Global Overactive Bladder Treatment Market Size by Distribution Channel & CAGR (2025-2032)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Overactive Bladder Treatment Market Size & CAGR (2025-2032)

North America (Treatment Type, Route of Administration, Distribution Channel)
- US
- Canada
Europe (Treatment Type, Route of Administration, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Treatment Type, Route of Administration, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Treatment Type, Route of Administration, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Treatment Type, Route of Administration, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Astellas Pharma (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medtronic Plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sumitomo Pharma Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hisamitsu Pharmaceutical Co., Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Endo International plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lupin Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dr. Reddy's Laboratories Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Coloplast (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Axonics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boston Scientific (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kyorin Pharmaceutical Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Macleods Pharmaceuticals Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Organon (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Viatris Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments